Ayelet Chajut
No más puestos en curso
Perfil
Ayelet Chajut worked as Vice President-Research at Pluri, Inc., Vice President-Research at Quark Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Rosetta Genomics Ltd.
She holds a doctorate degree from Tel-Aviv University.
Antiguos cargos conocidos de Ayelet Chajut.
| Empresas | Cargo | Fin |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Director Técnico/Científico/I+D | - |
| PLURI INC. | Director Técnico/Científico/I+D | - |
| ROSETTA GENOMICS LTD. | Director Técnico/Científico/I+D | - |
Formación de Ayelet Chajut.
| Tel-Aviv University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ROSETTA GENOMICS LTD. | Health Technology |
| PLURI INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Ayelet Chajut
